Trial · NCT06385236
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
NCT06385236, Phase 4, Recruiting, University of California, San Diego
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping. Trials, record NCT06385236. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06385236
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
- NCT number
- NCT06385236
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 120 participants, estimated
- Lead sponsor
- University of California, San Diego
- Conditions
- Moderate to Severe Asthma
- Interventions
- Dupilumab, Benralizumab
- First posted
- 2024-04-26
- Last updated
- 2024-08-19
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Predicting asthma outcomes and therapeutic responses | After 16 weeks (for each biologic) | The primary outcomes of our therapeutic assessments are the genomic signatures that will identify novel predictive biomarkers and provide mechanistic insights to the heterogeneous response to a specific therapy. Our genomic signatures will focus on global gene expression using RNA sequencing (RNA-Seq). |
| Primary | Responses to the biologic therapies at the single cell level | After 16 weeks (for each biologic) | Single cell (sc) RNA-Seq on sputum and blood samples will be assayed at baseline and after each evoked (drug) phenotype. |
| Primary | Unique asthma subgroups clinical and molecular endotype approaches | After 16 weeks (for each biologic) | Clinical and molecular endotype will be independently assessed for their prognostic association with treatment response through scRNA-seq and RNA-sequencing data at baseline and following therapy. |
| Secondary | Asthma Control Questionnaire (ACQ) | Assessed through study completion, an average of 60 weeks | A simple questionnaire (6-item questionnaire) to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment |
| Secondary | CompEx events | Assessed through study completion, an average of 60 weeks | CompEx is a composite outcome specific to asthma that combines clinically relevant deteriorations captured by diary events with exacerbations, thereby providing an increase in power compared to using exacerbations alone. CompEx events include exacerbations and deterioration events. |
| Secondary | Asthma Quality of Life Questionnaire (AQLQ) | Assessed through study completion, an average of 60 weeks | A disease-specific health-related quality of life instrument that taps both physical and emotional impact of disease. (32 items with 2-week recall) |
| Secondary | Forced expiratory volume in 1 second (FEV1) | Assessed through study completion, an average of 60 weeks | Lung function (FEV1) will be measured prior to bronchodilator administration by spirometry test. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01HL161362 | Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | TANTISIRA, KELAN G; BLEECKER, EUGENE ROLAND; CHUPP, GEOFFREY L; WEISS, SCOTT T | UNIVERSITY OF CALIFORNIA, SAN DIEGO | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2022 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06385236
GET https://conductscience.org/api/trials/v1/NCT06385236/registered